CNS Metastases – Biocept

The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCs) of Patients with Leptomeningeal Metastasis Having Solid Tumors; Implications for Treating the LM Tumor with Anti_HER2 Therapy

Society for Neuro-Oncology 2022

BioceptNovember 22, 2022

The Detection of Disseminated Pineal Parenchymal Tumor of Intermediate Differentiation (PPTID) in Cerebrospinal Fluid (CSF) Using Cell Capture and Immunocytochemistry

Society for Neuro-Oncology 2022

BioceptNovember 22, 2022

Detection of Mutant p53 Positive Glioblastoma Cells in Cerebrospinal Fluid (CSF) Using a Microfluidic Based Immunoassay

Society for Neuro-Oncology 2022

BioceptNovember 22, 2022

Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ Assay

Clinical Breast Cancer 2022

BioceptAugust 26, 2022

Using Cerebrospinal Fluid Tumor Cell (CSF-TC) Assays to Track Disease Burden and Treatment Response in Patients with Leptomeningeal Metastasis

American Academy of Neurology 2022

BioceptApril 7, 2022

Characterization of HER2 Amplification in the Cerebrospinal Fluid of Patients with Leptomeningeal Disease in Stage IV Patients with Breast Cancer

San Antonio Breast Cancer Symposium 2021

BioceptDecember 8, 2021

Case Series of Multi-Institutional Utility of CNSide™ to Manage Leptomeningeal Disease in Patients with Metastatic Breast Cancer

Society for Neuro-Oncology 2021

BioceptNovember 25, 2021

Beyond Cytology – A Single Institution Experience Using CNSide™ for Diagnosing and Monitoring Treatment Response in Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis (LMC)

SNO Brain Metastases 2021

BioceptAugust 23, 2021